Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer

NCT00126230 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: docetaxel and samarium

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris